<?xml version="1.0" encoding="UTF-8"?>
<p>More than three-quarters of EU support for research on NIDs (€121.7 million) was invested in projects that could be classified as product development of new drugs, vaccines and diagnostics (
 <xref rid="t0010" ref-type="table">Table 2</xref>). Just 5% of funding (€9.4 million) was invested in basic research activities, mainly through ERC grants and Marie Curie actions. Vaccines constituted the largest focus area across diseases, with a total funding of more than €61 million. All projects included various elements of capacity building, but projects with a dedicated focus on research training and strengthening of research infrastructure in endemic regions received €13.1 million.
</p>
